GHP November 2016

8 | ghp November 2016 Janssen’s Next- Generation Biologic Guselkumab Shows Promise in the Treatment of Psoriatic Arthritis Data from the trial also showed statistically significant improvements in all secondary endpoints including physical function, psoriatic skin lesions and other health related outcomes, compared with patients receiving placebo. The guselkumab Phase 2 results in active psoriatic arthritis follow positive Phase 3 study results in moderate to severe plaque psoriasis recently presented at the European Academy of Dermatology and Venereology Congress in Vienna. “Guselkumab is one of a new class of biologic therapies which target the protein interleukin (IL)-23, and the Phase 2 results are promising as they demonstrate a significant improvement in the treatment of active psoriatic arthritis,” said Atul Deodhar, MD, MRCP, FACP, FACR, Professor of Medicine, Oregon Health & Science University and lead study author.* “It’s encouraging to see how well patients responded to guselkumab in this study with respect to improvements in disease signs and symptoms, as early as week four, and in other health- related quality of life outcomes, including measures of physical and mental health.” Patients treated with guselkumab had significantly greater improvements in enthesitis (inflammation of the entheses, the sites at which tendons or ligaments attach to bone) and dactylitis (inflammation of the fingers or toes), and in health-related quality of life as measured by SF-36 physical component summary (SF36-PCS) scores and mental component summary (SF36-MCS) scores compared with patients treated with placebo at week 24. In addition, a greater percentage of patients in the guselkumab group achieved MDA (Minimal Disease Activity) compared with the placebo group at week 24 (23% versus 2%, respectively, [P = 0.001]). MDA for psoriatic arthritis is a composite measure encompassing clinically important aspects of the disease, including arthritis, psoriasis, enthesitis, pain, patient-assessed global disease activity, and physical function. Safety observations through week 24 showed that 36.0% versus 32.7% experienced adverse events (AEs), in the guselkumab and placebo groups, respectively. The most common AEs were infections. Two serious AEs were reported including one knee injury and one myocardial infarction. Investigators remain blinded to individual treatment group assignments, as the study is ongoing. In both treatment groups, there were no reported serious infections, malignancies, or deaths through week 24. “The efficacy and safety results from this Phase 2 study show the potential of guselkumab in the treatment of active psoriatic arthritis,” said Newman Yielding MD, head of immunology development, Janssen. “We plan to advance guselkumab into a Phase 3 psoriatic arthritis development programme next year to further characterise this novel monoclonal antibody’s profile in the treatment of this complex inflammatory disease.” Janssen-Cilag International NV (Janssen) announced in mid- November positive efficacy and safety results from a Phase 2 study investigating guselkumab, an anti-interleukin (IL)-23 monoclonal antibody administered by subcutaneous injection, for the treatment of active psoriatic arthritis. According to findings presented at the 2016 American College of Rheumatology (ACR) Annual Meeting, 58% of patients receiving guselkumab achieved at least a 20% improvement in signs and news